⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Official Title: A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease

Study ID: NCT04663997

Conditions

Prostate Cancer

Study Description

Brief Summary: 177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body. The purpose of this study is to find out whether 177Lu PSMA 617can slow the growth of prostate cancer compared to standard chemotherapy treatment

Detailed Description: The standard or usual treatment for this disease is a chemotherapy drug called docetaxel, given by intravenous every 3 weeks, for up to 12 treatments. 177Lu-PSMA-617 is a new type of therapy for prostate cancer. Laboratory tests show that it may help slow the growth of prostate cancer. 177Lu-PSMA-617 has been shown to shrink tumours in animals and has been studied in limited numbers of men with prostate cancer and seems promising but it is not clear if it can offer better control of prostate cancer compared to docetaxel chemotherapy .

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: MALE

Healthy Volunteers: No

Locations

Tom Baker Cancer Centre, Calgary, Alberta, Canada

Cross Cancer Institute, Edmonton, Alberta, Canada

BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

London Regional Cancer Program, London, Ontario, Canada

Odette Cancer Centre, Toronto, Ontario, Canada

University Health Network, Toronto, Ontario, Canada

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada

The Jewish General Hospital, Montreal, Quebec, Canada

Hotel-Dieu de Quebec, Quebec City, Quebec, Canada

CIUSSS de l'Estrie - Centre hospitalier, Sherbrooke, Quebec, Canada

Contact Details

Name: Kim Chi

Affiliation: BCCA - Vancouver Cancer Centre, BC Canada

Role: STUDY_CHAIR

Name: Francois Benard

Affiliation: BCCA - Vancouver Cancer Centre, BC Canada

Role: STUDY_CHAIR

Name: Fred Saad

Affiliation: CHUM-Centre Hospitalier de l'Universite de Montreal, Canada

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: